OTCMKTS:BIOQ

Bioqual Competitors

$91.00
+5.50 (+6.43 %)
(As of 05/7/2021 08:28 PM ET)
Add
Compare
Today's Range
$90.00
$91.00
50-Day Range
$85.50
$87.80
52-Week Range
$60.00
$92.00
Volume200 shs
Average Volume356 shs
Market Capitalization$81.54 million
P/E Ratio17.37
Dividend Yield1.21%
Beta-0.33

Competitors

Bioqual (OTCMKTS:BIOQ) Vs. CBWTF, PIRS, CBLI, ELOX, ARFXF, and NNVC

Should you be buying BIOQ stock or one of its competitors? Companies in the industry of "commercial physical research" are considered alternatives and competitors to Bioqual, including Auxly Cannabis Group (CBWTF), Pieris Pharmaceuticals (PIRS), Cleveland BioLabs (CBLI), Eloxx Pharmaceuticals (ELOX), ProMIS Neurosciences (ARFXF), and NanoViricides (NNVC).

Bioqual (OTCMKTS:BIOQ) and Auxly Cannabis Group (OTCMKTS:CBWTF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.

Volatility & Risk

Bioqual has a beta of -0.33, indicating that its share price is 133% less volatile than the S&P 500. Comparatively, Auxly Cannabis Group has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Profitability

This table compares Bioqual and Auxly Cannabis Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bioqual9.12%17.62%9.81%
Auxly Cannabis Group-332.96%-47.37%-28.34%

Insider & Institutional Ownership

0.0% of Auxly Cannabis Group shares are held by institutional investors. 39.2% of Bioqual shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Bioqual and Auxly Cannabis Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bioqual0000N/A
Auxly Cannabis Group00303.00

Auxly Cannabis Group has a consensus target price of $0.40, suggesting a potential upside of 29.37%. Given Auxly Cannabis Group's higher possible upside, analysts clearly believe Auxly Cannabis Group is more favorable than Bioqual.

Earnings and Valuation

This table compares Bioqual and Auxly Cannabis Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioqual$46.36 million1.76$4.23 millionN/AN/A
Auxly Cannabis Group$6.29 million36.85$-77,300,000.00N/AN/A

Bioqual has higher revenue and earnings than Auxly Cannabis Group.

Summary

Bioqual beats Auxly Cannabis Group on 7 of the 12 factors compared between the two stocks.

Bioqual (OTCMKTS:BIOQ) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Insider and Institutional Ownership

57.5% of Pieris Pharmaceuticals shares are owned by institutional investors. 39.2% of Bioqual shares are owned by company insiders. Comparatively, 6.6% of Pieris Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Bioqual and Pieris Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioqual$46.36 million1.76$4.23 millionN/AN/A
Pieris Pharmaceuticals$46.28 million2.64$-25,470,000.00($0.56)-3.45

Bioqual has higher revenue and earnings than Pieris Pharmaceuticals.

Risk and Volatility

Bioqual has a beta of -0.33, meaning that its stock price is 133% less volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500.

Profitability

This table compares Bioqual and Pieris Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bioqual9.12%17.62%9.81%
Pieris Pharmaceuticals-59.11%-55.20%-21.21%

Analyst Ratings

This is a summary of current ratings and price targets for Bioqual and Pieris Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bioqual0000N/A
Pieris Pharmaceuticals00203.00

Pieris Pharmaceuticals has a consensus target price of $9.00, suggesting a potential upside of 366.32%. Given Pieris Pharmaceuticals' higher possible upside, analysts plainly believe Pieris Pharmaceuticals is more favorable than Bioqual.

Summary

Bioqual beats Pieris Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Cleveland BioLabs (NASDAQ:CBLI) and Bioqual (OTCMKTS:BIOQ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Cleveland BioLabs and Bioqual, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cleveland BioLabs0000N/A
Bioqual0000N/A

Earnings & Valuation

This table compares Cleveland BioLabs and Bioqual's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cleveland BioLabs$1.11 million76.51$-2,650,000.00N/AN/A
Bioqual$46.36 million1.76$4.23 millionN/AN/A

Bioqual has higher revenue and earnings than Cleveland BioLabs.

Volatility & Risk

Cleveland BioLabs has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Bioqual has a beta of -0.33, suggesting that its share price is 133% less volatile than the S&P 500.

Profitability

This table compares Cleveland BioLabs and Bioqual's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cleveland BioLabs-382.26%-123.97%-86.26%
Bioqual9.12%17.62%9.81%

Insider & Institutional Ownership

2.6% of Cleveland BioLabs shares are owned by institutional investors. 1.0% of Cleveland BioLabs shares are owned by insiders. Comparatively, 39.2% of Bioqual shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Bioqual beats Cleveland BioLabs on 6 of the 9 factors compared between the two stocks.

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Bioqual (OTCMKTS:BIOQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Insider & Institutional Ownership

21.5% of Eloxx Pharmaceuticals shares are held by institutional investors. 33.4% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 39.2% of Bioqual shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Eloxx Pharmaceuticals and Bioqual, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eloxx Pharmaceuticals02102.33
Bioqual0000N/A

Eloxx Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 164.55%. Given Eloxx Pharmaceuticals' higher probable upside, equities research analysts clearly believe Eloxx Pharmaceuticals is more favorable than Bioqual.

Earnings and Valuation

This table compares Eloxx Pharmaceuticals and Bioqual's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eloxx PharmaceuticalsN/AN/A$-50,870,000.00($1.34)-1.41
Bioqual$46.36 million1.76$4.23 millionN/AN/A

Bioqual has higher revenue and earnings than Eloxx Pharmaceuticals.

Volatility & Risk

Eloxx Pharmaceuticals has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500. Comparatively, Bioqual has a beta of -0.33, meaning that its share price is 133% less volatile than the S&P 500.

Profitability

This table compares Eloxx Pharmaceuticals and Bioqual's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eloxx PharmaceuticalsN/A-163.87%-89.65%
Bioqual9.12%17.62%9.81%

Summary

Bioqual beats Eloxx Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

ProMIS Neurosciences (OTCMKTS:ARFXF) and Bioqual (OTCMKTS:BIOQ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Valuation and Earnings

This table compares ProMIS Neurosciences and Bioqual's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMIS NeurosciencesN/AN/A$-5,570,000.00N/AN/A
Bioqual$46.36 million1.76$4.23 millionN/AN/A

Bioqual has higher revenue and earnings than ProMIS Neurosciences.

Risk and Volatility

ProMIS Neurosciences has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Bioqual has a beta of -0.33, meaning that its stock price is 133% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for ProMIS Neurosciences and Bioqual, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMIS Neurosciences0000N/A
Bioqual0000N/A

Profitability

This table compares ProMIS Neurosciences and Bioqual's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMIS NeurosciencesN/AN/A-436.74%
Bioqual9.12%17.62%9.81%

Insider and Institutional Ownership

0.0% of ProMIS Neurosciences shares are owned by institutional investors. 39.2% of Bioqual shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Bioqual beats ProMIS Neurosciences on 7 of the 9 factors compared between the two stocks.

NanoViricides (NYSEAMERICAN:NNVC) and Bioqual (OTCMKTS:BIOQ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares NanoViricides and Bioqual's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NanoViricidesN/A-43.79%-38.50%
Bioqual9.12%17.62%9.81%

Analyst Ratings

This is a summary of current ratings and price targets for NanoViricides and Bioqual, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NanoViricides0000N/A
Bioqual0000N/A

Valuation & Earnings

This table compares NanoViricides and Bioqual's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NanoViricidesN/AN/A$-13,450,000.00N/AN/A
Bioqual$46.36 million1.76$4.23 millionN/AN/A

Bioqual has higher revenue and earnings than NanoViricides.

Risk and Volatility

NanoViricides has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Bioqual has a beta of -0.33, indicating that its stock price is 133% less volatile than the S&P 500.

Insider and Institutional Ownership

7.3% of NanoViricides shares are held by institutional investors. 5.6% of NanoViricides shares are held by company insiders. Comparatively, 39.2% of Bioqual shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Bioqual beats NanoViricides on 6 of the 8 factors compared between the two stocks.


Bioqual Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Auxly Cannabis Group logo
CBWTF
Auxly Cannabis Group
1.4$0.31+1.1%$231.81 million$6.29 million-2.21Gap Down
Pieris Pharmaceuticals logo
PIRS
Pieris Pharmaceuticals
1.4$1.93+3.1%$122.18 million$46.28 million-3.64Gap Up
Cleveland BioLabs logo
CBLI
Cleveland BioLabs
0.6$5.49+3.8%$84.93 million$1.11 million0.00
Eloxx Pharmaceuticals logo
ELOX
Eloxx Pharmaceuticals
1.3$1.89+8.5%$76.01 millionN/A-1.89Analyst Downgrade
High Trading Volume
ProMIS Neurosciences logo
ARFXF
ProMIS Neurosciences
0.0$0.15+2.7%$44.59 millionN/A-7.29Upcoming Earnings
NNVC
NanoViricides
0.4$3.63+0.0%$38.76 millionN/A0.00
AIkido Pharma logo
AIKI
AIkido Pharma
1.0$0.91+3.3%$31.86 million$10,000.000.00Gap Down
Tenax Therapeutics logo
TENX
Tenax Therapeutics
1.4$2.06+2.9%$30.84 millionN/A-1.70
Inhibitor Therapeutics logo
INTI
Inhibitor Therapeutics
0.0$0.08+6.5%$28.19 millionN/A0.00
HPPI
HedgePath Pharmaceuticals
0.4$0.09+25.1%$27.78 millionN/A0.00High Trading Volume
Gap Up
U.S. Stem Cell logo
USRM
U.S. Stem Cell
0.6$0.04+11.1%$16.76 million$6.70 million0.00
Vitality Biopharma logo
VBIO
Vitality Biopharma
0.5$0.15+0.0%$7.59 million$260,000.000.00Gap Up
Protalex logo
PRTX
Protalex
0.9$0.01+0.0%$615,000.00N/A0.00
DNAG
DNAPrint Genomics
0.0$0.00+25.0%$518,000.00N/A0.00
ALGXY
Affinity Energy and Health
0.4$0.00+169,900.0%$0.00$2.05 million0.00Gap Down
DGEN
Deltagen
0.2$0.00+34.9%$0.00N/A0.00Gap Down
RPBC
Redpoint Bio
0.5$0.00+0.0%$0.00N/A0.00
This page was last updated on 5/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.